NanoViricides is a clinical-stage pharmaceutical company developing a novel class of antiviral drugs it calls nanoviricides. The company has no approved products and no revenue. Its lead candidate, NV-387, is a broad-spectrum antiviral that mimics the surface receptors (sulfated proteoglycans) that viruses attach to as a first step in infection — tricking the virus into binding to the drug instead of a real cell, where it is then dismantled. Because this mechanism targets the host-side receptor rather than the virus itself, NanoViricides argues NV-387 is structurally resistant to viral mutations, a key limitation of most existing antivirals and vaccines. NV-387 has completed Phase I safety trials with no adverse events and is preparing to enter Phase II trials for MPox in the Democratic Republic of Congo and for respiratory infections (influenza, RSV, coronaviruses) via a basket trial design. The company's second candidate, NV-HHV-1, is a skin cream for shingles that has completed preclinical studies. NanoViricides funds operations through equity raises and a founder credit line. Its intended revenue model combines pharma licensing deals (facilitated by business development firm Aagami), U.S. government biodefense contracts via BARDA, and royalties from a licensing arrangement with Indian partner Karveer Meditech. The company owns a cGMP-capable manufacturing facility in Shelton, Connecticut. Core IP is exclusively licensed from TheraCour Pharma, a related party controlled by founder Dr. Anil Diwan.